Logo for Akebia Therapeutics Inc

Akebia Therapeutics Investor Relations Material

Latest events

Logo for Akebia Therapeutics Inc

Q1 2024

Akebia Therapeutics
Logo for Akebia Therapeutics

Q1 2024

9 May, 2024
Logo for Akebia Therapeutics

FDA Announcement

28 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Akebia Therapeutics Inc

Access all reports
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product candidate include Vadadustat, an oral therapy for the treatment of anemia due to chronic kidney disease in non-dialysis and dialysis patients; and AKB-9778, which is intended for the treatment of hypoxia-inducible factor stabilization. Its clinical programs also comprise AKB-6548, for the treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis; AKB-5169 for the treatment of pain associated with osteoarthritis; and AKB-6899 for use as a bioavailable prodrug of oxaloacetate to treat disorders accompanied by oxidative stress.